Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$236.34 USD

236.34
2,258,170

-5.84 (-2.41%)

Updated Sep 4, 2024 04:00 PM ET

After-Market: $236.50 +0.16 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

by Zacks Equity Research

Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

    Medical Device Industry Outlook - June 2018

    by Zacks Equity Research

    The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.

      Why Is Becton, Dickinson (BDX) Down 2.4% Since its Last Earnings Report?

      by Zacks Equity Research

      Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Becton, Dickinson (BDX) Beats on Q2 Earnings & Revenues

        by Zacks Equity Research

        Becton, Dickinson (BDX) gains on solid segmental performance; raises fiscal 2018 guidance.

          What's in Store for DENTSPLY (XRAY) This Earnings Season?

          by Zacks Equity Research

          DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.

            Should You Sell Becton, Dickinson (BDX) Before Earnings?

            by Zacks Equity Research

            Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

              Cigna to Take Over Express Scripts (ESRX) for $67 Billion

              by Zacks Equity Research

              Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.

                Becton, Dickinson (BDX) Down 1.3% Since Last Earnings Report

                by Zacks Equity Research

                Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4

                  by Zacks Equity Research

                  Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.

                    Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View

                    by Zacks Equity Research

                    Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.

                      Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid

                      by Zacks Equity Research

                      Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.

                        Mark Vickery headshot

                        MedTech's Long-Term Prospects Outweigh Near-Term Risks

                        by Mark Vickery

                        A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.

                          STERIS Focuses on Expanding Core Business, Competition Rife

                          by Zacks Equity Research

                          STERIS (STE) pursues six acquisitions in the first nine months of fiscal 2018.

                            Here's Why You Should Invest in LabCorp (LH) Stock Right Now

                            by Zacks Equity Research

                            Strong guidance and Covance Drug Development's sturdy growth raise investors optimism on LabCorp (LH).

                              Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

                              by Zacks Equity Research

                              Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.

                                AmerisourceBergen (ABC) Jumps: Stock Rises 9.3%

                                by Zacks Equity Research

                                AmerisourceBergen (ABC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

                                  GNC Holdings to Boost International Business With New Deals

                                  by Zacks Equity Research

                                  GNC Holdings (GNC) adopts initiatives to boost contributions from international business with strong focus on China.

                                    GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates

                                    by Zacks Equity Research

                                    Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.

                                      CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat

                                      by Zacks Equity Research

                                      A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.

                                        Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View

                                        by Zacks Equity Research

                                        Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.

                                          STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up

                                          by Zacks Equity Research

                                          STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.

                                            CAH vs. HOLX: Which Will Fare Better This Earnings Season?

                                            by Zacks Equity Research

                                            Here we look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

                                              Becton (BDX) Beats on Q1 Earnings and Revenues Estimates

                                              by Zacks Equity Research

                                              Becton, Dickinson and Company (BDX) delivers strong performance in Q1 on the back strong segmental performance.

                                                Medical Product Stocks' Earnings on Feb 6: BDX, LH & More

                                                by Zacks Equity Research

                                                Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs.

                                                  Should You Buy Becton, Dickinson (BDX) Ahead of Earnings?

                                                  by Zacks Equity Research

                                                  Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.